Poxel SA (POXEL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Poxel SA (POXEL) has a cash flow conversion efficiency ratio of -0.124x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€7.59 Million ≈ $8.87 Million USD) by net assets (€-61.40 Million ≈ $-71.79 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Poxel SA defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Poxel SA - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Poxel SA's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Poxel SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Poxel SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pensonic Holdings Bhd
KLSE:9997
|
-0.029x |
|
Intrasense
PA:ALINS
|
0.452x |
|
Copaur Minerals Inc
V:CPAU
|
-0.008x |
|
Acrinova AB
ST:ACRI-A
|
0.092x |
|
Park Ha Biological Technology Co., Ltd.
NASDAQ:PHH
|
-12.940x |
|
Winhitech Co Ltd
KQ:192390
|
-0.079x |
|
Way 2 Vat Ltd
AU:W2V
|
-1.805x |
|
Yorkton Equity Group Inc
V:YEG
|
0.052x |
Annual Cash Flow Conversion Efficiency for Poxel SA (2011–2024)
The table below shows the annual cash flow conversion efficiency of Poxel SA from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Poxel SA.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €-58.94 Million ≈ $-68.90 Million |
€-17.61 Million ≈ $-20.58 Million |
0.299x | +4.88% |
| 2023-12-31 | €-49.08 Million ≈ $-57.38 Million |
€-13.98 Million ≈ $-16.34 Million |
0.285x | -76.18% |
| 2022-12-31 | €-18.24 Million ≈ $-21.33 Million |
€-21.81 Million ≈ $-25.50 Million |
1.196x | +158.09% |
| 2021-12-31 | €8.21 Million ≈ $9.59 Million |
€-16.89 Million ≈ $-19.75 Million |
-2.059x | -114.90% |
| 2020-12-31 | €26.88 Million ≈ $31.42 Million |
€-25.75 Million ≈ $-30.10 Million |
-0.958x | -45.94% |
| 2019-12-31 | €39.14 Million ≈ $45.76 Million |
€-25.69 Million ≈ $-30.04 Million |
-0.656x | -671.83% |
| 2018-12-31 | €55.78 Million ≈ $65.22 Million |
€-4.74 Million ≈ $-5.55 Million |
-0.085x | -120.23% |
| 2017-12-31 | €19.33 Million ≈ $22.60 Million |
€8.13 Million ≈ $9.50 Million |
0.420x | +187.86% |
| 2016-12-31 | €39.39 Million ≈ $46.05 Million |
€-18.85 Million ≈ $-22.04 Million |
-0.479x | -80.88% |
| 2015-12-31 | €38.03 Million ≈ $44.46 Million |
€-10.06 Million ≈ $-11.76 Million |
-0.265x | -111.07% |
| 2014-12-31 | €-2.55 Million ≈ $-2.98 Million |
€-6.09 Million ≈ $-7.12 Million |
2.390x | +614.70% |
| 2013-12-31 | €-20.01 Million ≈ $-23.39 Million |
€-6.69 Million ≈ $-7.82 Million |
0.334x | +101.87% |
| 2012-12-31 | €315.03K ≈ $368.30K |
€-5.64 Million ≈ $-6.60 Million |
-17.912x | -1489.45% |
| 2011-12-31 | €7.35 Million ≈ $8.59 Million |
€-8.28 Million ≈ $-9.68 Million |
-1.127x | -- |
About Poxel SA
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic pathophysiology, type 2 diabetes, and liver diseases. It also develops treatments for rare metabolic diseases and associated steatohepatitis to metabolic dysfunction. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the tr… Read more